Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

Autor Luke, Jason J.
Vydáno v Oncologist (2019)

Considering adjuvant therapy for stage II melanoma

Autor Poklepovic, Andrew S., Luke, Jason J.
Vydáno v Cancer (2019)

Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response

Autor Garris, Christopher S., Luke, Jason J.
Vydáno v Clin Cancer Res (2020)

Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone

Autor Luke, Jason, Mirkin, Joshua, Bach, Peter
Vydáno 2011

Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

Autor Luke, Jason J., Schwartz, Gary K.
Vydáno 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

Autor Luke, Jason J, Keohan, Mary-Louise
Vydáno 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Autor Luke, Jason J., Hodi, F. Stephen
Vydáno 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

Autor Luke, Jason J, Ott, Patrick A
Vydáno 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

Autor Luke, Jason J., Ott, Patrick A.
Vydáno v Oncotarget (2015)

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

Autor Sweis, Randy F., Luke, Jason J.
Vydáno v Pharmacol Res (2017)

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development

Autor Olson, Daniel J, Luke, Jason J
Vydáno v Immunotherapy (2019)

Improving therapy in metastatic uveal melanoma by understanding prior failures

Autor Olson, Daniel J., Luke, Jason J.
Vydáno v Oncoscience (2020)

Toll-Like Receptor 9 Agonists in Cancer

Autor Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Vydáno v Onco Targets Ther (2020)

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

Autor Bao, Riyue, Stapor, Daniel, Luke, Jason J.
Vydáno v Genome Med (2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

Autor Labadie, Brian W., Bao, Riyue, Luke, Jason J.
Vydáno v Clin Cancer Res (2018)

PD-1 Blockade in Chinese versus Western Patients with Melanoma

Autor Shoushtari, Alexander N., Bao, Riyue, Luke, Jason J.
Vydáno v Clin Cancer Res (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Autor Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Vydáno v Front Oncol (2021)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

Autor Bao, Riyue, Hernandez, Kyle, Huang, Lei, Luke, Jason John
Vydáno v J Immunother Cancer (2020)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

Autor Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Vydáno v J Immunother Cancer (2016)

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

Autor Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
Vydáno v Front Immunol (2021)